Updated survival analyses of a multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first-line chemotherapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) (CHEIRON study)

被引：0
|
作者：
Caffo, O. [1 ]
Palesandro, E. [2 ]
Nole, F. [3 ]
Gasparro, D. [4 ]
Mucciarini, C. [5 ]
Aieta, M. [6 ]
Zagonel, V. [7 ]
Iacovelli, R. [8 ]
De Giorgi, U. F. F. [9 ]
Rossetti, S. [10 ]
Fratino, L. [11 ]
Ermacora, P. [12 ]
Nicodemo, M. [13 ]
Giordano, M. [14 ]
Sartori, D. [15 ]
Scapoli, D. [16 ]
Verri, E. [3 ]
Maines, F. [17 ]
Pappagallo, G.
Aglietta, M. [18 ]
机构：
[1] Osped Santa Chiara, Med Oncol, Trento, Italy
[2] IRCCS Candiolo, Dipartimento Oncol Med, Candiolo, Italy
[3] Ist Europeo Oncol, Med Oncol, Milan, Italy
[4] AOU Parma, Med Oncol, Parma, Italy
[5] Osped Ramazzini, Med Oncol, Carpi, Italy
[6] Ctr Riferimento Oncol Basilicata IRCCS, Med Oncol, Rionero In Vulture, Italy
[7] Ist Oncol Veneto IRCCS, Med Oncol, Padua, Italy
[8] Fdn Policlin Agostino Gemelli, IRCCS, Rome, Italy
[9] Ist Tumori Romagna IRST, Dept Med Oncol, Meldola, Forli Cesena, Italy
[10] Fdn Pascale, Unita Dipartimentale Uroandrol, Naples, Italy
[11] CRO, Med Oncol, Aviano, Italy
[12] AOU Udine, Med Oncol, Udine, Italy
[13] Negrar Canc Ctr, Med Oncol, Negrar, Italy
[14] Presidio Osped Osped St Anna, Med Oncol, San Fermo Battaglia, Italy
[15] Osped Civiile Dolo, Med Oncol, Dolo, Italy
[16] Azienda Osped Ferrara St Anna, Med Oncol, Ferrara, Italy
[17] Osped Santa Chiara, Oncol, Trento, Italy
[18] Ist Candiolo FPO IRCCS, Med Oncol, Candiolo, Italy
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
854P
引用
收藏
页码：333 / 333
页数：1
相关论文
共 50 条
  • [31] Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone
    Massard, C.
    Mateo, J.
    Loriot, Y.
    Pezaro, C.
    Albiges, L.
    Mehra, N.
    Varga, A.
    Bianchini, D.
    Ryan, C. J.
    Petrylak, D. P.
    Attard, G.
    Shen, L.
    Fizazi, K.
    de Bono, J.
    ANNALS OF ONCOLOGY, 2017, 28 (01) : 90 - 95
  • [32] Phase III SYNERGY trial: Docetaxel ± custirsen and overall survival in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and poor prognosis.
    Chi, Kim N.
    Higano, Celestia S.
    Blumenstein, Brent A.
    Reeves, James Andrew
    Feyerabend, Susan
    Gravis, Gwenaelle
    Ferrero, Jean-Marc
    Jacobs, Cindy
    De Bono, Johann Sebastian
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [33] Phase I trial with a combination of docetaxel and 153Sm- EDTMP in patients (pts) with castration-resistant metastatic prostate cancer (mCRPC)
    Eisenberger, M. A.
    Lin, J.
    Sinibaldi, V. J.
    Carducci, M. A.
    Denmeade, S.
    DeWeese, T.
    Song, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [34] A phase II study of sunitinib (SU) for maintenance therapy in metastatic castration-resistant prostate cancer (mCRPC) after response to docetaxel (D)
    Eigl, B. J.
    Trudeau, M. G.
    Winquist, E.
    Chi, K. N.
    Eliasziw, M.
    North, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [35] TAXYNERGY: Randomized trial of early switch from first-line docetaxel (D) to cabazitaxel (C) or vice versa with circulating tumor cell (CTC) biomarkers in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
    Tagawa, Scott T.
    Antonarakis, Emmanuel S.
    Saad, Fred
    Vanhuyse, Marie
    Sonpavde, Guru
    North, Scott A.
    Albany, Costantine
    Tsao, Che-Kai
    Stewart, John
    Zaher, Atef
    Szatrowski, Ted P.
    Zhou, Wei
    Galletti, Giuseppe
    Worroll, Daniel
    Eisenberger, Mario A.
    Nanus, David M.
    Giannakakou, Paraskevi
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [36] First-line use of cabazitaxel in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (mCRPC): A three-arm study in comparison with docetaxel
    Oudard, Stephane
    Sengelov, Lisa
    Mainwaring, Paul N.
    Thiery-Vuillemin, Antoine
    Theodore, Christine
    Kulikov, Evgeny
    Yachnin, Jeffrey
    Kocak, Ivo
    Kataja, Vesa V.
    Luukkaa, Marjaana
    Nosov, Aleander
    Hjelm-Eriksson, Marie
    Bubis, Jeffrey
    Shen, Liji
    Risse, Marie-Laure
    Sartor, A. Oliver
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [37] Chemotherapy-Induced Neutropenia and Outcome in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With First-Line Docetaxel
    Buttigliero, Consuelo
    Tucci, Marcello
    Vignani, Francesca
    Di Stefano, Rosario F.
    Leone, Gianmarco
    Zichi, Clizia
    Pignataro, Daniele
    Lacidogna, Gaetano
    Guglielmini, Pamela
    Numico, Gianmauro
    Scagliotti, Giorgio, V
    Di Maio, Massimo
    CLINICAL GENITOURINARY CANCER, 2018, 16 (04) : 318 - 324
  • [38] EQ-5D UTILITY INDEX IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) WITH PROGRESSION DURING OR AFTER FIRST-LINE DOCETAXEL THERAPY
    James, N.
    Eisenberger, M.
    Fizazi, K.
    Heidenreich, A.
    Joulain, F.
    Laizet, C.
    VALUE IN HEALTH, 2011, 14 (07) : A457 - A458
  • [39] Evaluating the safety of abiraterone acetate (AA) and docetaxel (D) administered in combination in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC)
    Tagawa, Scott T.
    Nanus, David M.
    Posadas, Edwin M.
    Petrylak, Daniel Peter
    Bruce, Justine Yang
    Lim, Emerson A.
    Peng, Weimin
    Maul, Raymond Scott
    Gonzalez, Martha
    Tran, Namphuong
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [40] Final analysis of COMET-1: Cabozantinib (Cabo) versus prednisone (Pred) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E).
    Smith, Matthew Raymond
    De Bono, Johann Sebastian
    Sternberg, Cora N.
    Le Moulec, Sylvestre
    Oudard, Stephane
    De Giorgi, Ugo
    Krainer, Michael
    Bergman, Andre M.
    Hoelzer, Wolfgang
    De Wit, Ronald
    Boegemann, Martin
    Saad, Fred
    Cruciani, Giorgio
    Thiery-Vuillemin, Antoine
    Feyerabend, Susan
    Miller, Kurt
    Ramies, David Albert
    Hessel, Colin
    Weitzman, Aaron
    Fizazi, Karim
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
12345